Search

Learn how an MSK laboratory is bringing much-needed focus to cancer-related lymphedema and investigating new ways to prevent the complication.

… Thursday, October 18, 2018 Summary Lymphedema caused by cancer treatment is an often-debilitating condition that can last for years or decades. A dedicated research laboratory at MSK is clarifying how this puzzling disease develops and testing new therapies that could reduce or prevent its effects. Lymphedema

In an eagerly awaited study, Memorial Sloan Kettering researchers report on the molecular structure of mTOR, a protein commonly mutated in cancer.

… Thursday, May 30, 2013 Summary In an eagerly awaited study, Memorial Sloan Kettering researchers report on the molecular structure of mTOR, a protein commonly mutated in cancer. For the first time, structural biologists at Memorial Sloan Kettering have revealed the molecular structure of mTOR, a protein

Learn about a new initiative led by MSK pediatric hematologic oncologist Tanya Trippett that aims to improve cancer care and research in Ghana.

… Friday, February 28, 2020 Summary A new initiative led by Memorial Sloan Kettering pediatric hematologic oncologist Tanya Trippett aims to improve cancer care and research in the West African nation. Cancer doesn’t discriminate. Few people are more keenly aware of this fact than Memorial Sloan Kettering

Memorial Sloan Kettering Cancer Center (MSK) announces the return of NYC for MSK to celebrate MSK’s 141st anniversary.

… Tuesday, June 3, 2025 Memorial Sloan Kettering Cancer Center (MSK) announces the return of  NYC for MSK  to celebrate MSK’s 141st anniversary. For one day, New York City’s most notable brands in fashion, food, toys, and sports will come together to support MSK’s mission of ending cancer for life. On

A new study led by MSK investigators reveals how some cancer cells become resistant to targeted treatment and suggests what might be done to stop that from happening.

… Thursday, April 9, 2015 Summary Most cancers treated with targeted therapy ultimately become resistant to treatment, stop shrinking, and eventually progress. New research led by investigators at Memorial Sloan Kettering shows how melanoma and lung cancer cells that initially respond to targeted therapies

Chemotherapy is among the most commonly prescribed, and commonly misunderstood, cancer treatments. It’s time to revise what you thought you knew.

… Tuesday, August 30, 2016 Summary Chemotherapy drugs have evolved considerably over the years. Now, we can treat patients with little to no interference in their everyday lives. We have made great strides in treating cancer with chemotherapy drugs, yet myths about these medications still remain. Donna

Discover how cyclist Stacia Smart turned her grief into purpose after her boyfriend died of a brain tumor.

… Friday, January 1, 2021 Bright, athletic, gregarious, and kind, Owen Strong was enjoying a quintessential life in Manhattan. Living with college friends from Tufts, he was working in the family real estate business and recording songs with his band, the Evening Fools. Then, in February 2018, at age 28

It’s not every day that scientists discover a new part of the cell. Two biologists from the Sloan Kettering Institute just did.

… Thursday, November 15, 2018 Summary Scientists at the Sloan Kettering Institute have discovered a new organelle. The finding challenges longstanding ideas about cell structure. Many people probably remember cell organelles from high school biology. Mitochondria are a cell’s “energy factories.” The nucleus

Learn how a novel drug is showing promise against lung and pancreatic cancer in early clinical trials by targeting the KRAS G12D mutation with a KRAS degrader.

… Wednesday, March 25, 2026 A new drug is showing promise in lung and pancreatic cancers — two of the most aggressive forms of cancer — by targeting one of the most common cancer-driving mutations. Setidegrasib, formerly known as ASP3082, tags and destroys the cancer-causing protein produced by the KRAS

… Thursday, March 12, 2009 Student Research Eric Alonzo Eric Alonzo Recent publications from our students. Eric Alonzo Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, Chua K, Eidson M, Kim HJ, Im JS, Pandolfi PP, Sant’Angelo DB. The BTB-zinc finger transcriptional regulator PLZF controls the